Coronavirus Update: Remdesivir Fast-Tracked, GSK's Shingrix Hit Hard By Lockdown
Plus J&J Expands Manufacturing Capacity
Results from the first major trial of remdesivir are positive, but fail to show clear mortality benefit - making its forthcoming approval just the first step towards winning the war on COVID-19.
